Ionis Partners with Sobi for Olezarsen to Treat Familial Chylomicronemia Syndrome (FCS) & Severely Elevated Triglycerides
Shots:
- Ionis has granted Sobi global exclusive rights of olezarsen excl. the US, Canada & China to treat familial chylomicronemia syndrome (FCS) & severely elevated triglycerides; Ionis to independently market Olezarsen in the US, whereas Theratechnologies holds the rights in Canada
- As per the deal, Ionis will get an upfront, with potential milestone payments & net sales-based tiered royalties while Sobi will handle future regulatory filings & marketing in its licensed regions
- Additionally, Olezarsen’s MAA is under EMA review & is being evaluated in 3 P-III trials for severe hypertriglyceridemia: ESSENCE (data expected by mid-2025), plus CORE & CORE2 (data of both anticipated in H2’25).
Ref: Businesswire | Image: Ionis & Sobi
Related News:- Sobi Reports the US FDA’s sNDA Acceptance of Doptelet (Avatrombopag) to Treat Pediatric Immune Thrombocytopenia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
